Published in Proc Natl Acad Sci U S A on August 05, 2003
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood (2006) 5.21
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol (2007) 4.45
Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol (2008) 4.10
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
ER stress-induced cell death mechanisms. Biochim Biophys Acta (2013) 3.07
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell (2015) 2.63
pXBP1(U) encoded in XBP1 pre-mRNA negatively regulates unfolded protein response activator pXBP1(S) in mammalian ER stress response. J Cell Biol (2006) 2.62
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood (2010) 2.48
Fine-tuning of the unfolded protein response: Assembling the IRE1alpha interactome. Mol Cell (2009) 2.47
Unfolded protein response in a Drosophila model for retinal degeneration. EMBO J (2006) 2.45
Regulation of basal cellular physiology by the homeostatic unfolded protein response. J Cell Biol (2010) 2.40
Genetic interactions due to constitutive and inducible gene regulation mediated by the unfolded protein response in C. elegans. PLoS Genet (2005) 2.33
Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One (2009) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
The transcription factor XBP-1 is essential for the development and survival of dendritic cells. J Exp Med (2007) 2.12
The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J (2011) 2.08
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum (2012) 2.03
Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. J Virol (2006) 2.02
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. Int J Cell Biol (2010) 1.86
Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med (2005) 1.86
Activation of specific apoptotic caspases with an engineered small-molecule-activated protease. Cell (2010) 1.85
A review of the mammalian unfolded protein response. Biotechnol Bioeng (2011) 1.83
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood (2012) 1.81
Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol (2011) 1.80
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol Biol Cell (2007) 1.75
Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur J Immunol (2008) 1.71
XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med (2009) 1.71
ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis and directs intestinal stem cells. J Exp Med (2013) 1.70
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Dual and opposing roles of the unfolded protein response regulated by IRE1alpha and XBP1 in proinsulin processing and insulin secretion. Proc Natl Acad Sci U S A (2011) 1.59
Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem (2011) 1.58
PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics (2004) 1.57
The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem (2009) 1.55
Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol (2014) 1.54
Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res (2010) 1.47
Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res (2012) 1.47
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int (2005) 1.46
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood (2014) 1.45
Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response. J Immunol (2009) 1.44
Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica (2010) 1.42
Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad Sci U S A (2010) 1.41
p38 MAPK-mediated regulation of Xbp1s is crucial for glucose homeostasis. Nat Med (2011) 1.41
The ER stress factor XBP1s prevents amyloid-beta neurotoxicity. Hum Mol Genet (2011) 1.40
The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (2007) 1.40
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res (2008) 1.34
Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. Semin Immunol (2009) 1.33
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood (2008) 1.31
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica (2011) 1.31
Endoplasmic reticulum stress and intestinal inflammation. Mucosal Immunol (2009) 1.27
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.26
Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol (2008) 1.23
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther (2013) 1.21
Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J (2011) 1.19
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1α. EMBO J (2012) 1.17
Emerging roles for XBP1, a sUPeR transcription factor. Gene Expr (2010) 1.17
Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther (2006) 1.16
A Bacteriophage tailspike domain promotes self-cleavage of a human membrane-bound transcription factor, the myelin regulatory factor MYRF. PLoS Biol (2013) 1.16
Pharmacological ER stress promotes hepatic lipogenesis and lipid droplet formation. Am J Transl Res (2012) 1.15
Preventing oxidative stress: a new role for XBP1. Cell Death Differ (2009) 1.15
Up-regulation of the clusterin gene after proteotoxic stress: implication of HSF1-HSF2 heterocomplexes. Biochem J (2006) 1.14
Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res (2009) 1.14
Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. J Biol Chem (2007) 1.13
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J Oncol (2011) 1.11
Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol (2006) 1.11
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Transl Oncol (2009) 1.10
Selective abrogation of BiP/GRP78 blunts activation of NF-κB through the ATF6 branch of the UPR: involvement of C/EBPβ and mTOR-dependent dephosphorylation of Akt. Mol Cell Biol (2011) 1.10
Proteasome inhibitors and cardiac cell growth. Cardiovasc Res (2009) 1.10
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J (2012) 1.09
XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation. J Biol Chem (2012) 1.09
The role of X-box binding protein-1 in tumorigenicity. Drug News Perspect (2009) 1.09
Control of cellular GADD34 levels by the 26S proteasome. Mol Cell Biol (2008) 1.09
Endoplasmic reticulum stress regulator XBP-1 contributes to effector CD8+ T cell differentiation during acute infection. J Immunol (2008) 1.08
From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis. Ann N Y Acad Sci (2009) 1.08
Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol (2011) 1.08
1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis (2008) 1.07
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07
Monitoring and manipulating mammalian unfolded protein response. Methods Enzymol (2011) 1.05
C/EBP homologous protein (CHOP) contributes to suppression of metabolic genes during endoplasmic reticulum stress in the liver. J Biol Chem (2012) 1.04
Evolving treatment strategies for myeloma. Br J Cancer (2005) 1.04
Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig (2010) 1.03
Endoplasmic reticulum stress-induced cell death mediated by the proteasome. Cell Death Differ (2007) 1.03
Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Horm Mol Biol Clin Investig (2011) 0.97
Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clin Cancer Res (2011) 0.97
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood (2008) 0.97
ER stress depresses NF-kappaB activation in mesangial cells through preferential induction of C/EBP beta. J Am Soc Nephrol (2009) 0.97
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood (2012) 0.97
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma. Mol Med (2012) 0.94
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther (2013) 0.94
Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol (2006) 0.93
Degradation of Alzheimer's amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes. Mol Biol Cell (2011) 0.93
XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell (2001) 18.68
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature (1999) 16.97
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature (2002) 16.52
Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (2000) 13.62
Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature (2000) 13.45
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol (2000) 11.62
Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell (1993) 9.84
Plasma cell differentiation requires the transcription factor XBP-1. Nature (2001) 9.72
ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell (2000) 9.13
A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A (2002) 8.57
A novel mechanism for regulating activity of a transcription factor that controls the unfolded protein response. Cell (1996) 8.17
The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature (1988) 7.98
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol (2003) 7.06
ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell (2002) 6.95
IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev (2002) 6.37
A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase/endoribonuclease (Ire1p) in mammalian cells. Genes Dev (1998) 5.88
Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol (1998) 5.66
Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell (2001) 5.39
Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 5.22
Proteasome inhibitors: from research tools to drug candidates. Chem Biol (2001) 5.06
Activation of ATF6 and an ATF6 DNA binding site by the endoplasmic reticulum stress response. J Biol Chem (2000) 4.37
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Block of HAC1 mRNA translation by long-range base pairing is released by cytoplasmic splicing upon induction of the unfolded protein response. Cell (2001) 3.45
Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem (2000) 3.40
ATF6 as a transcription activator of the endoplasmic reticulum stress element: thapsigargin stress-induced changes and synergistic interactions with NF-Y and YY1. Mol Cell Biol (2000) 2.89
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol (2002) 2.88
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem (1997) 2.80
IRE1 and efferent signaling from the endoplasmic reticulum. J Cell Sci (2000) 2.46
Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42
Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity (2003) 2.40
Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Natl Acad Sci U S A (1997) 2.31
Identification and characterization of a novel endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro and is induced by ER stress. J Biol Chem (2002) 1.99
Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J Exp Med (1996) 1.95
Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol (2001) 1.52
Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur J Biochem (1998) 1.41
Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol (2002) 1.41
Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol Med (1997) 1.35
MDG1/ERdj4, an ER-resident DnaJ family member, suppresses cell death induced by ER stress. Genes Cells (2003) 1.29
Not just research tools--proteasome inhibitors offer therapeutic promise. Nat Med (2002) 1.12
Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem (2000) 1.02
Inhibition of etoposide-induced apoptosis with peptide aldehyde inhibitors of proteasome. Biochem J (1998) 0.99
Moving disease biology from the laboratory to the clinic. Semin Oncol (2002) 0.88
Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett (1999) 0.87
High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol (2002) 0.83
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (2004) 19.08
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol (2003) 11.17
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell (2007) 8.42
Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science (2002) 8.34
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol (2003) 7.06
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity (2004) 6.43
Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol (2001) 6.30
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Regulation of hepatic lipogenesis by the transcription factor XBP1. Science (2008) 6.02
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med (2004) 5.13
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Homeostasis and inflammation in the intestine. Cell (2010) 4.60
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol (2010) 4.56
Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe (2010) 4.54
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science (2006) 4.46
T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol (2002) 4.38
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol (2008) 4.09
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
XBP-1 is required for biogenesis of cellular secretory machinery of exocrine glands. EMBO J (2005) 3.92
Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science (2002) 3.91
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
NFATc1 balances quiescence and proliferation of skin stem cells. Cell (2008) 3.81
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat Immunol (2006) 3.70
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science (2005) 3.65
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A (2003) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
The role of Th1/Th2 polarization in mucosal immunity. Nat Med (2002) 3.19
Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med (2002) 3.16
Critical roles for transcription factor GATA-3 in thymocyte development. Immunity (2003) 3.15
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Mol Cell (2009) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev (2009) 3.03
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood (2005) 2.95
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72
Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science (2006) 2.70
T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat Immunol (2010) 2.68
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood (2007) 2.65
T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci U S A (2002) 2.63
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood (2009) 2.61
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (2010) 2.51
The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiol Rev (2011) 2.50
Fine-tuning of the unfolded protein response: Assembling the IRE1alpha interactome. Mol Cell (2009) 2.47
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol (2008) 2.45
Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer (2002) 2.42
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica (2006) 2.40
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc Natl Acad Sci U S A (2003) 2.34
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest (2008) 2.29
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood (2009) 2.28
A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med (2008) 2.26
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25